🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New KRASG12C inhibitor D3S-001 shines! (Nature Medicine, 2025) Results: NSCLC (naive): 66.7% ORR CRC (naive): 88.9% ORR PDAC: 75% ORR Post-G12Ci NSCLC: 30% ORR ✅ No DLTs ✅ Good CNS activity ✅ High ctDNA clearance Next-gen G12C inhibitor to watch! #OncoTwitter #KRAS #LungCancer

RAS Inhibition: Response & Resistance 🟡Primary (10–20%): KEAP1, PI3K, TP53, SMARCA4 mutations. 🟠Acquired (~60%): KRAS muts (25–30%), RTKs (20–25%), PI3K (10–15%), MYC, EMT & MAPK pathway. 🔜Rational combos and next-gen RAS inhibitors are key aacrjournals.org/cancerdiscover…

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC

🚨‼️FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression #PrecisionMedicine OncoAlert onclive.com/view/fda-grant… via @onclive

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

In a recent study (May 2025) published in Nature Genetics, Nomura et al.(Roel Verhaak , Lavarone, Mario Suva , Tirosh Lab labs) leveraged single-nucleus RNA sequencing and bulk tumor DNA sequencing to unveil new dimensions of GBM complexity. The team discovered three previously

🧠 An article discussing the molecular interactions between metastases and immune cells within the leptomeninges is now available in @nature.com. 🔗 nature.com/articles/s4158… #EANOessentials #glioblastoma #NeuroOncology #leptomeningeal #metastases

Very important paper!

Carcinoma of Unknown Primary: Cancer without a past 🧬 Early dissemination 🛡️Immune editing of the primary 🧪CK20+, CDX2+, SATB2+ → treat colon-like 🧭Let biology, not anatomy, guide therapy Not a diagnostic failure — a metastatic strategy. nejm.org/doi/full/10.10… #ASCO25

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬 1/15 🚨 Here's a shocking fact: Rare cancers make up 25% of ALL cancer cases, yet most patients never get the molecular testing that could save their lives. 👉In our policy & practice paper -

Can a cancer exploit its environment and still resist treatment? Yes, through co-existing malignant subclones! Let me walk you through our latest study on how divergent evolution drives aggressiveness, and drug resistance of T cell cancer. 1/🧵 doi.org/10.1158/2159-8…

HER2 IHC 3+ testing in 65,000+ solid tumors shows a 3.1% positivity rate Most common➡️Bladder (13.9%), uterine serous (13.6%), GEJ (12.1%). Least common➡️Glioma, sarcoma, SCLC(0%) 📌Bx and resection samples yield largely similar HER2 positivity rates jamanetwork.com/journals/jamao…

Online Now: Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma dlvr.it/TLZk25

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020 buff.ly/XW3XLx3 The KBP-2020 study analyzed lung adenocarcinoma outcomes in over 5000 patients treated in nonacademic public hospitals in France and found that median overall survival more

New paper from our lab out Vall d’Hebron Institute of Oncology (VHIO) in Molecular Cancer Therapeutics! We investigate how #prostatecancer adapts to CDK4/6 inh, and how PARP inh can overcome it to kill residual tumor cells. Kudos to the whole team, especially Julian Brandariz (his first paper!) & Nicolás Herranz for leading the work!

🆕🗞️Published today JCO Precision Oncology ASCO The1️⃣st AGNOSTIC study of a PARP⛔️inhibitor: 📚LODESTAR: Rucaparib💊 🎯Need to think about variants in Homologous Recombination Repair (HRR) Genes 🧬 beyond canonical #BRCA #PALB2. 💡Novel insights. OncoAlert 🔗ascopubs.org/doi/10.1200/PO…

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…